Use in the prevention of influenza.

Promotes immunity to seasonal influenza virus by inducing specific antibody production. Each year the formulation is standardized according to the US Public Health Service.

Onset of action: Most adults have antibody protection within 2 weeks of vaccination.
Duration: 6 to 8 months when vaccine is antigenically similar to circulating virus; response may be diminished in persons ≥65 years of age and limited evidence suggests titers may decline significantly 6 months following vaccination in this population.

Severe allergic reaction (eg, anaphylaxis) to a previous influenza vaccination or to any component of the formulation.

B/C

Administration does not affect the safety of breastfeeding for the mother or the infant.

Fever, headache, myalgia, malaise, sweating, fatigue, shivering, nasal congestion, runny nose reactions at the site of the injection (swelling, pain, hardening and redness)

Administration:
This vaccine is administered subcutaneously or intramuscularly.
Dosage:
For children of age ≥3 and for adults, one dose of 0.5 mL of vaccine is injected.
Note:
1. For children of age < 9 previously unvaccinated with any seasonal flu vaccine, two doses should be administered.
2. Each dose should be administered at least 4 weeks apart.